目的 探討加減香砂六君子湯治療新型冠狀病毒肺炎（COVID-19）恢復期肺脾氣虛證的作用機制。方法 利用TCMSP數(shù)據(jù)庫篩選中藥活性成分和靶點，利用Gendcars、OMIM數(shù)據(jù)庫篩選疾病靶點，STRING平臺對靶點進行PPI網(wǎng)絡構(gòu)建，并進行GO和KEGG分析，利用Cytoscape 3.7.2軟件構(gòu)建“藥物-活性成分-靶點-疾病”網(wǎng)絡圖，然后通過拓撲學參數(shù)分析獲得加減香砂六君子湯主要活性成分和靶點，最后將主要活性成分與靶點進行分子對接驗證。結(jié)果 得到槲皮素、木犀草素、山柰酚、柚皮素等115個活性成分，PTGS2、NOS2、PPARG、PTGS1、MAPK14等48個靶點，主要涉及IL-17、TNF、T細胞受體、MAPK、VEGF等155條通路。分子對接顯示，槲皮素、木犀草素、山柰酚、柚皮素與3CL水解酶、ACE2、PTGS2具有較好的結(jié)合活性，與第七版推薦抗病毒藥物結(jié)合能相近。結(jié)論 加減香砂六君子湯活性成分可通過與3CL水解酶、ACE2、PTGS2結(jié)合，調(diào)控IL-17、TNF、T細胞受體、MAPK、VEGF等信號通路來抑制炎癥反應，調(diào)節(jié)機體免疫，減輕肺損傷，促進細胞生長分化和肺血管生成，從而改善患者癥狀，促進恢復期患者康復，提高機體免疫力，降低疾病復發(fā)或再感染的風險。

Objective To explore the mechanism of modified Xiangsha Liujunzi Decoction on COVID-19 with lung and spleen Qi deficiency syndrome in recovery period. Methods This study searched TCMSP database for the active components and targets, searched Gendcars and OMIM databases for disease targets, used STRING and Cytoscape 3.7.2 to build PPI and "drug-ingredienttarget-disease" network diagram, performed GO and KEGG analysis. Main active components and targets were then obtained by calculating topological parameters. Finally, main active components and targets were identified by molecular docking. Result 115 active components including quercetin, luteolin, kaempferol, naringenin, and 48 targets including PTGS2, NOS2, PPARG, PTGS1, MAPK14 were predicted. IL-17, TNF, T cell receptor, MAPK, VEGF signal pathways were involved. Active components have good binding activity with 3CL hydrolase, ACE2, PTGS2. Conclusion Binding with 3CL hydrolase, ACE2, PTGS2, modified Xiangsha Liujunzi Decoction regulate IL-17, TNF, T cell receptor, MAPK, VEGF pathways to inhibit inflammatory response, regulate body immunity, reduce lung injury, promote cell growth and differentiation and pulmonary angiogenesis, improve the symptoms of patients, promote the recovery of patients, improve the body immunity, reduce the risk of disease recurrence or reinfection.

R285.5

國家自然科學基金青年基金（81303073）；河南省科技攻關項目（92102310161；182102310291）；河南省中醫(yī)藥科學研究專項（20-21ZY1015；20-21ZY2004）